Production (Stage)
Statera Biopharma, Inc.
STAB
$0.0001
$0.000.00%
OTC PK
09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
---|---|---|---|---|---|
Net Income | 3.97% | 55.04% | 89.96% | -507.24% | -92.58% |
Total Depreciation and Amortization | 46.30% | 9.07% | 6.09% | -18.78% | 6,875.00% |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 8.56% | -258.35% | -99.32% | 3,807.97% | -23.34% |
Change in Net Operating Assets | -22.89% | 13.94% | -11.07% | 189.00% | -413.17% |
Cash from Operations | -375.67% | 95.52% | 48.89% | 51.65% | -403.72% |
Capital Expenditure | -- | 100.00% | 93.29% | -53.08% | -249.72% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -100.00% | 2,337.37% |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -- | 100.00% | 93.29% | -100.74% | 2,410.57% |
Total Debt Issued | -100.00% | -- | -- | -- | -100.00% |
Total Debt Repaid | -- | 100.00% | -1,062.94% | -718.83% | -- |
Issuance of Common Stock | 1,287.33% | -99.21% | 625.86% | -86.22% | -- |
Repurchase of Common Stock | -- | 0.00% | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | 200.00% | -- | -- | 100.00% |
Cash from Financing | 42.31% | 117.25% | -3,342.17% | -86.69% | -96.28% |
Foreign Exchange rate Adjustments | -39.63% | 367.82% | -455.32% | -135.00% | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -111.88% | 106.00% | 9.21% | -389.71% | -109.67% |